| Fluvastatin N = 78 | Placebo N = 78 | P |
---|---|---|---|
Demographical data | Â | Â | Â |
Age (years; mean ± SD) | 60.9 ± 11.5 | 63.2 ± 11.3 | ns. |
Gender | Â | Â | ns. |
   Male | 70.5 | 65.4 |  |
   Female | 29.5 | 34.6 |  |
Weight (kg; mean ± SD) | 84.1 ± 13.2 | 82.7 ± 14.9 | ns. |
Smoking status | Â | Â | ns. |
   Current smoker | 42.3 | 50.0 |  |
   Non-smoker | 43.6 | 39.7 |  |
   Former smoker | 14.1 | 10.3 |  |
History | Â | Â | Â |
IHD | 16.7 | 25.6 | ns. |
MI | 5.1 | 10.3 | ns. |
PCI | 1.3 | 5.1 | ns. |
CABG | 0 | 1.3 | ns. |
Diabetes | 17.9 | 20.5 | ns. |
Hypercholesterolemia | 11.5 | 11.5 | ns. |
Hypertension | 51.3 | 51.3 | ns. |
Stroke | 3.8 | 2.6 | ns. |
PVD | 2.6 | 2.6 | ns. |
Clinical data | Â | Â | Â |
Heart rate (bpm; mean ± SD) | 76.1 ± 18.1 | 72.2 ± 16.5 | ns. |
SBP (mmHg; mean ± SD) | 138.4 ± 29.2 | 141.1 ± 25.2 | ns. |
DBP (mmHg; mean ± SD) | 81.9 ± 17.4 | 80.8 ± 18.0 | ns. |
Acute coronary syndrome type | Â | Â | ns. |
   STE ACS | 60.3 | 69.2 |  |
   Non-STE ACS | 39.7 | 30.8 |  |
Duration of symptoms (Hrs; mean ± SD) | 10.1 ± 8.9 | 8.0 ± 5.9 | ns. |
Killip class | Â | Â | ns. |
   Killip I | 88.5 | 87.2 |  |
   Killip II | 9.0 | 11.5 |  |
   Killip III | 1.3 | 0 |  |
   Killip IV | 1.3 | 1.3 |  |
Total cholesterol at admission (mmol/L; mean ± SD) | 5.5 ± 1.3 | 5.4 ± 1.1 | ns. |
Troponin I at admission (μg/L; mean ± SD) | 14.7 ± 29.1 | 8.3 ± 14.1 | ns. |
Peak troponin I (μg/L; mean ± SD) | 78.3 ± 110.8 | 78.7 ± 93.9 | ns. |
LV ejection fraction (mean ± SD) | 48.0 ± 11.4 | 49.0 ± 10.9 | ns. |
Therapy | Â | Â | Â |
Coronary angiography | 98.7 | 98.7 | ns. |
Coronary intervention | 87.2 | 91.0 | ns. |
   PCI | 75.6 | 87.2 | 0.098 |
   CABG | 11.5 | 3.8 | 0.130 |
ASA | 98.7 | 98.7 | ns. |
IIb/IIIa inhibitors | 5.1 | 5.1 | ns. |
UFH/LMWH | 82.1 | 84.6 | ns. |
Beta-blockers | 88.5 | 88.5 | ns. |
Diuretics | 6.4 | 16.7 | 0.077 |
Clopidogrel | 71.8 | 84.6 | 0.080 |
ACE inhibitors | 66.7 | 69.2 | ns. |
Vyšš à odborná škola | 53 | 52 | +1 |